Concepedia

Yang-Min Ning

YN

Statistics

Publications

4

Citations

812

H-Index

4

Active since

2010

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

National Cancer Institute

Yang-Min Ning is an author at United States Food and Drug Administration specializing in medicine, pharmacology, and systems biology.

Top concepts

Publications per year

2010–2019

4

Publications

4

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

V. Ellen Maher, Laura L. Fernandes, Chana Weinstock et al. · Journal of Clinical Oncology · 2019 · 336 citations

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy

Daniel L. Suzman, Sundeep Agrawal, Yang-Min Ning et al. · The Oncologist · 2018 · 199 citations · Full text

Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

Yang-Min Ning, James L. Gulley, Philip M. Arlen et al. · Journal of Clinical Oncology · 2010 · 145 citations · Full text

, , +12

Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells

Johanny Tonos De Leon, Aki Iwai, Clémentine Féau et al. · Proceedings of the National Academy of Sciences · 2011 · 132 citations

, , +15

1–4 of 4